Literature DB >> 24757110

The spectrum of cognitive impairment in Lewy body diseases.

Jennifer G Goldman1, Caroline Williams-Gray, Roger A Barker, John E Duda, James E Galvin.   

Abstract

Cognitive impairment represents an important and often defining component of the clinical syndromes of Lewy body disorders: Parkinson's disease and dementia with Lewy bodies. The spectrum of cognitive deficits in these Lewy body diseases encompasses a broad range of clinical features, severity of impairment, and timing of presentation. It is now recognized that cognitive dysfunction occurs not only in more advanced Parkinson's disease but also in early, untreated patients and even in those patients with pre-motor syndromes, such as rapid eye movement behavior disorder and hyposmia. In recent years, the concept of mild cognitive impairment as a transitional or pre-dementia state in Parkinson's disease has emerged. This has led to much research regarding the diagnosis, prognosis, and underlying neurobiology of mild cognitive impairment in Parkinson's disease, but has also raised questions regarding the usefulness of this concept and its application in clinical and research settings. In addition, the conundrum of whether Parkinson's disease dementia and dementia with Lewy bodies represent the same or different entities remains unresolved. Although these disorders overlap in many aspects of their presentations and pathophysiology, they differ in other elements, such as timing of cognitive, behavioral, and motor symptoms; medication responses; and neuropathological contributions. This article examines the spectrum and evolution of cognitive impairment in Lewy body disorders and debates these controversial issues in the field using point-counterpoint approaches.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; cognition; dementia; executive function; mild cognitive impairment

Mesh:

Year:  2014        PMID: 24757110      PMCID: PMC4126402          DOI: 10.1002/mds.25866

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  124 in total

1.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.

Authors:  H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

Review 2.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

Review 3.  Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.

Authors:  Teus van Laar; Peter Paul De Deyn; Dag Aarsland; Paolo Barone; James E Galvin
Journal:  CNS Neurosci Ther       Date:  2010-07-07       Impact factor: 5.243

4.  Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Authors:  Jacques Touchon; Howard Bergman; Roger Bullock; Günter Rapatz; Jennifer Nagel; Roger Lane
Journal:  Curr Med Res Opin       Date:  2006-01       Impact factor: 2.580

5.  Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden; Bryan Bernard; Bichun Ouyang; Christopher G Goetz; Glenn T Stebbins
Journal:  Mov Disord       Date:  2013-10-09       Impact factor: 10.338

Review 6.  Biomarkers in dementia with Lewy bodies: a review.

Authors:  Namrta Sinha; Michael Firbank; John T O'Brien
Journal:  Int J Geriatr Psychiatry       Date:  2011-07-01       Impact factor: 3.485

7.  Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease.

Authors:  Roberta Biundo; Luca Weis; Manuela Pilleri; Silvia Facchini; Patrizia Formento-Dojot; Annamaria Vallelunga; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2013-03-13       Impact factor: 3.575

8.  Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases.

Authors:  B Pillon; B Deweer; Y Agid; B Dubois
Journal:  Arch Neurol       Date:  1993-04

9.  Fronto-striatal cognitive deficits at different stages of Parkinson's disease.

Authors:  A M Owen; M James; P N Leigh; B A Summers; C D Marsden; N P Quinn; K W Lange; T W Robbins
Journal:  Brain       Date:  1992-12       Impact factor: 13.501

10.  Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.

Authors:  Enrique Noe; Karen Marder; Karen L Bell; Diane M Jacobs; Jennifer J Manly; Yaakov Stern
Journal:  Mov Disord       Date:  2004-01       Impact factor: 10.338

View more
  42 in total

Review 1.  Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.

Authors:  Jennifer G Goldman; Neelum T Aggarwal; Cynthia D Schroeder
Journal:  Neurodegener Dis Manag       Date:  2015-10-30

Review 2.  Chronic effects of mild neurotrauma: putting the cart before the horse?

Authors:  Rudy J Castellani; George Perry; Grant L Iverson
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

3.  Chronic traumatic encephalopathy: A paradigm in search of evidence?

Authors:  Rudy J Castellani
Journal:  Lab Invest       Date:  2015-04-13       Impact factor: 5.662

Review 4.  Parkinson's disease: what the model systems have taught us so far.

Authors:  Swagata Ghatak; Dorit Trudler; Nima Dolatabadi; Rajesh Ambasudhan
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 5.  Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Authors:  Jamie Eberling; Lona Vincent; Jennifer G Goldman; Daniel Weintraub; Jaime Kulisevsky; Connie Marras; Glenn Stebbins; Karl Kieburtz
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

6.  Introduction: the importance of cognition in movement disorders.

Authors:  David Burn; Daniel Weintraub; Trevor Robbins
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 7.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

8.  Subcortical matter in the α-synucleinopathies spectrum: an MRI pilot study.

Authors:  S Gazzina; E Premi; R Turrone; J Acosta-Cabronero; M C Rizzetti; M S Cotelli; R Gasparotti; A Padovani; B Borroni
Journal:  J Neurol       Date:  2016-05-26       Impact factor: 4.849

9.  α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B.

Authors:  Diana G Ferreira; Mariana Temido-Ferreira; Hugo Vicente Miranda; Vânia L Batalha; Joana E Coelho; Éva M Szegö; Inês Marques-Morgado; Sandra H Vaz; Jeong Seop Rhee; Matthias Schmitz; Inga Zerr; Luísa V Lopes; Tiago F Outeiro
Journal:  Nat Neurosci       Date:  2017-09-25       Impact factor: 24.884

Review 10.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.